Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30037075 | 0.77 | NR4A2 (0.43) | RPS6KA5ALDH1A1BTKL3MBTL1 | |
| SCHEMBL25552178 | 0.77 | NR4A2 (0.43) | RPS6KA5ALDH1A1BTKL3MBTL1 | |
| SCHEMBL30919844 | 0.71 | HTR5A (0.43) | RPS6KA5BTK | |
| SCHEMBL15648743 | 0.70 | MAPT (0.36) | POLBCASP6RPS6KA5ALDH1A1GAA | |
| SCHEMBL25551811 | 0.70 | RPS6KA5 (0.47) | RPS6KA5L3MBTL1 | |
| SCHEMBL30036735 | 0.70 | RPS6KA5 (0.47) | RPS6KA5L3MBTL1 | |
| SCHEMBL30919613 | 0.69 | RPS6KA5 (0.42) | RPS6KA5BTK | |
| SCHEMBL25559519 | 0.69 | CCNE1 (0.36) | — | |
| SCHEMBL29447959 | 0.69 | ALDH1A1 (0.44) | ALDH1A1CYP3A4CYP2C9CYP2C19MEN1 | |
| SCHEMBL615646 | 0.69 | ALDH1A1 (0.44) | ALDH1A1CYP3A4CYP2C9CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159508-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-05-25 | — | — | US | disclosed |
| US-20230159508-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-05-25 | — | — | US | disclosed |
| CN-115515940-A | Inhibitors of receptor interacting protein kinase I for the treatment of disease | 德州大学系统董事会 | 2022-12-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159508-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | RIPK1, RIPK2, RIPK4 | POLB 3352/4885CASP6 1144/4885RPS6KA5 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.